natgillin/translations-raw huggingface dataset:
Cmin: 0 8% (j 14 to 0 25) Norelgestromin (active metabolite): AUC: 0 64% (0 62 to 0 67)
Cmin: ↓ 8% (↑ 14 do ↓ 25) norelgestromin (aktivni metabolit): AUC: ↓ 64% (↓ 62 do ↓ 67)
Cmin: 0 86% (0 80 to 0 90) (induction of metabolism) Efavirenz: no clinically significant interaction.
Cmin: ↓ 86% (↓ 80 do ↓ 90) (indukcija metabolizma) efavirenz: nema klinički značajnih interakcija.
Cmin: 091% (088 to 092)
klaritromicinu (npr. azitromicin).
Cmin: 1.06 (0.88, 1.29)
Cmin: 1,06 (0,88, 1,29)
Cmin: 1.17 (1.03, 1.32)
Cmin: 1,17 (1,03, 1,32)
Cmin: 1.45 (1.25, 1.68)
Cmin: 1,45 (1,25, 1,68)
Cmin: 1.46 (1.12, 1.89)
Cmin: 1,46 1,12, 1,89)
Cmin: 2.68 (2.42, 2.98)
Cmin: 2,68 (2,42; 2,98)
Cmin: j 17%
Cmin: ↑ 17
Cmin: j 25% (j 7 to j 46) b
Cmin: ↓ 44
Cmin: N/A Cmax: ↑ 2%
Cmin: N/P Cmax: ↑ 2
Cmin: N/A Cmax: ↑ 21%
Cmin: N/P Cmax: ↑ 21
Cmin: N/A Cmax: ↑ 33%
Cmin: N/D Cmax: ↑ 33
Cmin: N/A Cmax: ↑ 89%
Cmin: N/D Cmax: ↑ 89
Cmin: N/A Cmax: ↓ 1%
Cmin: N/P Cmax: ↓ 1
Cmin: N/A Cmax: ↓ 14%
Cmin: N/P Cmax: ↓ 14
Cmin: N/A Cmax: ↓ 85%
Cmin: N/P Cmax: ↓ 85
Cmin: N/A Cmax: ↔
Cmin: N/P Cmax: ↔
Cmin: NA Cmax: ↑ 21%
Cmin: ND Cmax: ↑ 21
Cmin: NA Cmax: ↓ 14%
Cmin: ND Cmax: ↓ 14
Cmin: NA Cmax: ↓ 85%
Cmin: ND Cmax: ↓ 85
Cmin: NA Cmax: ↔
Cmin: ND Cmax: ↔
Cmin: Not determined
Cmin: nije određen
Cmin: ↑ 118% (↑ 91 to ↑ 150)
Cmin: ↑ 118% (od ↑ 91 do ↑ 150)
Cmin: ↑ 14.4-fold
Cmin: ↑ 14,4 puta
Cmin: ↑ 163% (↑ 137 to ↑ 197)
Cmin: ↑ 163% (od ↑ 137 do ↑ 197)
Cmin: ↑ 2%
Cmax: ↑ 2
Cmin: ↑ 25 % (↑ 7 to ↑ 46)b
Nije potrebno prilagođavati dozu raltegravira.
Cmin: ↑ 25% (↑ 7 to ↑ 46) (inhibition of CYP-mediated oxidative metabolism)
Cmin: ↑ 25% (↑ 7 do ↑ 46) (inhibicija oksidativnog metabolizma u kojem sudjeluju enzimi CYP)
Cmin: ↑ 3.5-fold Cmax: ↓ (relative to indinavir 800 mg TID
Cmin: ↑ 3,5 puta Cmax: ↓ (u odnosu na indinavir 800 mg TID sam)
Cmin: ↑ 3.5-fold Cmax: ↓ (relative to indinavir 800 mg TID alone)
Cmin: ↑ 3,5 puta Cmax: ↓ (u odnosu na indinavir 800 mg TID sam)
Cmin: ↑ 43%
polipeptida koji transportira
Cmin: ↑ 47% (↑ 38 to ↑ 57)
Cmin: ↑ 47% (od ↑ 38 do ↑ 57)
Cmin: ↑ 91% (↑ 74 to ↑ 110)
Cmin: ↑ 163% (od ↑ 137 do ↑ 197)
Cmin: ↓ 10% (↑ 1 to ↓ 19) (CYP3A induction by efavirenz)
Cmin: ↓ 10% (↑ 1 do ↓ 19) (CYP3A indukcija efavirenzom)
Cmin: ↓ 10% (↑ 1 to ↓ 19)% (CYP3A induction by efavirenz)
Cmin: ↓ 10% (↑ 1 do ↓ 19) (indukcija CYP3A efavirenzom)
Cmin: ↓ 12 % (↓ 24 to ↑ 1)
Cmin: ↓ 12% (↓ 24 do ↑ 1)
Cmin: ↓ 12% (↓ 24 to ↑ 1) (CYP3A4 induction)
Cmin: ↓ 12% (↓ 24 do ↑1) (indukcija CYP3A4)
Cmin: ↓ 15% (↓ 12 to ↓ 9)
Cmin: ↓ 15% (od ↓ 12 do ↓ 9)
Cmin: ↓ 15% (↓ 12 – ↓ 9)
Ribavirin/tenofovirdizoproksil
Cmin: ↓ 2% (↓ 9 to ↑ 6)
Cmin: ↓ 2% (od ↓ 9 do ↑ 6)
Cmin: ↓ 25% (↓ 14 to ↓ 34) Efavirenz:
Cmin: ↓ 25% (↓ 14 do ↓ 34) efavirenz:
Cmin: ↓ 25% (↓ 14 to ↓ 34)% Efavirenz:
Cmin: ↓ 25% (↓ 14 do ↓ 34)
Cmin: ↓ 25% (↓ 14 to ↓ 34)% Efavirenz:
Cmin: ↓ 25% (↓ 14 do ↓ 34) efavirenz:
Cmin: ↓ 26% (↓ 46 to ↑ 10)
Cmin: ↓ 26% (↓ 46 do ↑ 10)
Cmin: ↓ 32 % (↓ 15 to ↓ 46)
Cmin: ↓ 32% (↓ 15 do ↓ 46)
Cmin: ↓ 32 % (↓ 15 to ↓ 46) (CYP3A4 and CYP2B6 induction)
Cmin: ↓ 32% (↓ 15 do ↓ 46)
Cmin: ↓ 32% (↓ 15 to ↓ 46) (CYP3A4 and CYP2B6 induction)
Cmin: ↓ 32% (↓ 15 do ↓ 46)
Cmin: ↓ 32% (↓ 15 to ↓ 46) (CYP3A4 and CYP2B6 induction)
Cmin: ↓ 32% (↓ 15 do ↓ 46) (indukcija CYP3A4 i CYP2B6)
Cmin: ↓ 34% (↓ 43 to ↑ 24) Sofosbuvir:
Cmin: ↓ 34% (od ↓ 43 do ↑ 24) sofosbuvir:
Cmin: ↓ 35 % (↓ 24 to ↓ 44) Efavirenz:
Cmin: ↓ 35% (↓ 24 do ↓ 44) efavirenz:
Cmin: ↓ 35% (↓ 24 to ↓ 44)
Cmin: ↓ 35% (↓ 24 do ↓ 44)
Cmin: ↓ 35% (↓ 24 to ↓ 44) Efavirenz:
Cmin: ↓ 35% (↓ 24 do ↓ 44) efavirenz:
Cmin: ↓ 37 % (↓ 17 to ↓ 52) Efavirenz:
Cmin: ↓ 37% (↓ 17 do ↓ 52) efavirenz:
Cmin: ↓ 37% (↓ 17 to ↓ 52)
Cmin: ↓ 37% (↓ 17 do ↓ 52)
Cmin: ↓ 37% (↓ 17 to ↓ 52) Efavirenz:
Cmin: ↓ 37% (↓ 17 do ↓ 52) efavirenz:
Cmin: ↓ 4%
Cmax: ↓ 4
Cmin: ↓ 42 %* (↓ 31 to ↓ 51)
Cmin: ↓ 42%* (↓ 31 do ↓ 51)
Cmin: ↓ 43 % (↓ 18 to ↓ 60)
Cmin: ↓ 43% (↓ 18 do ↓ 60)
Cmin: ↓ 43%
manjenje doze glukokortikoida i
Cmin: ↓ 43% (↓ 18 to ↓ 60)
Cmin: ↓ 43% (↓ 18 do ↓ 60)
Cmin: ↓ 43% (↓ 18 to ↓ 60) Efavirenz:
Cmin: ↓ 43% (↓ 18 do ↓ 60) efavirenz:
Cmin: ↓ 44 % (↓ 27 to ↓ 58)
Cmin: ↓ 44% (↓ 27 do ↓ 58)
Cmin: ↓ 44% (↓ 27 to ↓ 58) (decrease in itraconazole concentrations: CYP3A4 induction) Hydroxyitraconazole:
Cmin: ↓ 44% (↓ 27 do ↓ 58) (smanjenje koncentracija itrakozanola: indukcija CYP3A4) hidroksiitrakonazol:
Cmin: ↓ 45 % (↓ 31 to ↓ 56)
Cmin: ↓ 45% (↓ 31 do ↓ 56)
Cmin: ↓ 45 % (↓ 31 to ↓ 56) Efavirenz:
Cmin: ↓ 45% (↓ 31 do ↓ 56)
Cmin: ↓ 45% (↓ 31 to ↓ 56)
Cmin: ↓ 45% (↓ 31 do ↓ 56)
Cmin: ↓ 45% (↓ 31 to ↓ 56) Efavirenz:
Cmin: ↓ 45% (↓ 31 do ↓ 56) efavirenz:
Cmin: ↓ 46 % (↓ 31 to ↓ 58) Efavirenz:
Cmin: ↓ 46% (↓ 31 do ↓ 58) efavirenz:
Cmin: ↓ 46% (↓ 31 to ↓ 58)
Cmin: ↓ 46% (↓ 31 do ↓ 58)
Cmin: ↓ 46% (↓ 31 to ↓ 58) Efavirenz:
Cmin: ↓ 46% (↓ 31 do ↓ 58) efavirenz:
Cmin: ↓ 47 % (↓ 41 to ↓ 53) (decrease in carbamazepine concentrations: CYP3A4 induction; decrease in efavirenz concentrations: CYP3A4 and CYP2B6 induction)
Cmin: ↓ 47% (↓ 41 do ↓ 53) (sniženje koncentracije karbamazepina: indukcija CYP3A4; sniženje koncentracije efavirenza: indukcija CYP3A4 i CYP2B6)
Cmin: ↓ 47% (↓ 41 to ↓ 53) (decrease in carbamazepine concentrations: CYP3A4 induction; decrease in efavirenz concentrations: CYP3A4 and CYP2B6 induction)
Cmin: ↓ 47% (↓ 41 do ↓ 53) (smanjenje koncentracija karbamazepina: indukcija CYP3A4; smanjenje koncentracije efavirenza: indukcija CYP3A4 i CYP2B6)
Cmin: ↓ 50% (↓ 40 to ↓ 59) b
Cmin: ↓ 50% (↓ 40 do ↓ 59) b
Cmin: ↓ 52%
tijekom dužeg vremenskog
Cmin: ↓ 62 % (↓ 44 to ↓ 75) N-monodesmethyl diltiazem: AUC: ↓ 37 % (↓ 17 to ↓ 52)
Cmin: ↓ 62% (↓ 44 do ↓ 75) N-monodezmetil diltiazem: AUC: ↓ 37% (↓ 17 do ↓ 52)
Cmin: ↓ 62% (↓ 44 to ↓ 75)
Cmin: ↓ 62% (↓ 44 do ↓ 75)
Cmin: ↓ 63 % (↓ 44 to ↓ 75) Desacetyl diltiazem:
Cmin: ↓ 63% (↓ 44 do ↓ 75) dezacetil-diltiazem:
Cmin: ↓ 63% (↓ 44 to ↓ 75)
Cmin: ↓ 63% (↓ 44 do ↓ 75)
Cmin: ↓ 63% (↓ 44 to ↓ 75) Desacetyl diltiazem:
Cmin: ↓ 63% (↓ 44 do ↓ 75) desacetildiltiazem:
Cmin: ↓ 7%
Cmax: ↓ 7
Cmin: ↓ 70%
(500/100 mg BID)
Cmin: ↓ 8 % (↑ 14 to ↓ 25) Norelgestromin (active metabolite):
Cmin: ↓ 8% (↑ 14 do ↓ 25)
Cmin: ↓ 8% (↑ 14 to ↓ 25) Norelgestromin (active metabolite): AUC: ↓ 64% (↓ 62 to ↓ 67)
Cmin: ↓ 8% (↑ 14 do ↓ 25) norelgestromin (aktivni metabolit): AUC: ↓ 64% (↓ 62 do ↓ 67)
Cmin: ↓ 82 % (↓ 79 to ↓ 85) Levonorgestrel (active metabolite): AUC: ↓ 83 % (↓ 79 to ↓ 87)
Cmin: ↓ 82% (↓ 79 do ↓ 85) levonorgestrel (aktivni metabolit): AUC: ↓ 83% (↓ 79 do ↓ 87)
Cmin: ↓ 82% (↓ 79 to ↓ 85)
Cmin: ↓ 82% (↓ 79 do ↓ 85)
Cmin: ↓ 82% (↓ 79 to ↓ 85) Levonorgestrel (active metabolite): AUC: ↓ 83% (↓ 79 to ↓ 87)
Cmin: ↓ 82% (↓ 79 do ↓ 85) levonorgestrel (aktivni metabolit): AUC: ↓ 83% (↓ 79 do ↓ 87)
Cmin: ↓ 86 % (↓ 80 to ↓ 90) (induction of metabolism) Efavirenz: no clinically significant interaction.
Cmin: ↓ 86% (↓ 80 do ↓ 90) (indukcija metabolizma) efavirenz: nema klinički značajnih interakcija.
Cmin: ↓ 86% (↓ 80 to ↓ 90) (induction of metabolism) Efavirenz: no clinically significant interaction.
Cmin: ↓ 86% (↓ 80 do ↓ 90) (indukcija metabolizma) efavirenz: ne postoji klinički značajna interakcija.
Cmin: ↓ 91% (↓ 88 to ↓ 92) Efavirenz:
Cmin: ↓ 91% (↓ 88 do ↓ 92)
Cmin: ↓ 91% (↓ 88 to ↓ 92) Efavirenz:
Cmin: ↓ 91% (↓ 88 do ↓ 92) efavirenz:
Cmin: ↔
dan)
Cmin: ↔
Pravastatin
Cmin: ↔ (CYP3A4 induction)
ANTIHISTAMINICI
Cmin: ↔ (CYP3A4 induction)
Cmin: ↔ (indukcija CYP3A4)
Cmin: ↔ Cmax: ↔
Cmin: ↔ Cmax:↔
CML in blast crisis and Ph+ ALL (starting dose 600 mg)
KML u blastičnoj krizi i Ph+ ALL (početna doza 600 mg)
CML in ‘chronic’, ‘accelerated’ and ‘blast’ phases.
CML u "kroničnoj", "ubrzanoj" i "blastičnoj" fazi.
CML is a leukaemia where granulocytes (a type of white blood cell) start growing out of control.
CML je leukemija u slučaju koje granulociti (tip bijelih krvnih stanica) počne nekontrolirano rasti.
CML-AP n=137 (%)
KML - ubrzana faza n=137 (%)
CML-CP and CML-AP
KML u kroničnoj i ubrzanoj fazi
CML-CP n=321 (%)
KML - kronična faza n=321 (%)
CNS adverse events
Nuspojave u SŽS-u
CNS adverse reactions
Nuspojave središnjeg živčanog sustava
CNS bleeding*b, syncope, tremor, amnesia, balance disorder
krvarenje u središnji živčani sustav*b, sinkope, tremor, amnezija, poremećaj ravnoteže
CNS depressant medicinal products
Depresori SŽS-a
CNS depression
Depresija središnjeg živčanog sustava
CNS influencing medical products
Lijekovi koji utječu na središnji živčani sustav
CNS medicinal products
Lijekovi koji djeluju na središnji živčani sustav (SŽS)
CNS symptoms such as seizures, lethargy, somnolence, depression, and encephalopathy have been associated with cysteamine.
Simptomi SŽS-a kao što su napadaji, letargija, pospanost, depresija i encefalopatija povezani su s cisteaminom.
CNS-LS scores range from a minimum of 7 (no symptoms) to a maximum of 35.
Rezultati CNS-LS kreću se u rasponu od najmanje 7 (bez simptoma) do najviše 35 bodova.
Co administration of PREZISTA co-administered with cobicistat and bosentan is not recommended.
Primjena lijeka PREZISTA istodobno primijenjenog s kobicistatom i bosentanom se ne preporučuje.
Co Armagh BT63 5UA
Do datuma
CO NDITIO NS OR RESTRIC TIO NS REGARDING SUPPLY AND USE
UVJETI ILI OGRANIČENJA VEZANI UZ OPSKRBU I PRIMJENU
CO NDITIO NS OR RESTRIC TIO NS WITH REGARD TO THE SAFE AND EFFEC TIV E USE O F THE MEDIC INAL PRO DUCT
UVJETI ILI OGRANIČENJA VEZANI UZ SIGURNU I UČINKOVITU PRIMJENU LIJEKA
Co Wicklow Ireland
Co Wicklow Irska
Co- administered
Istodobno primijenjeni lijek
Co- administered Medicinal Product
Istodobno primijenjen i lijek
Co- administered Medicinal Product
Istodobno primijenjeni lijek
Co- administration of aliskiren had no significant impact on atorvastatin, metformin or amlodipine pharmacokinetics.
Istodobna primjena aliskirena nije imala značajan utjecaj na farmakokinetiku atorvastatina, metformina ili amlodipina.
Co- administration of Aptivus and medicinal products that inhibit P-gp may increase tipranavir plasma concentrations.
Istodobna primjena Aptivusa i lijekova koji inhibiraju P-gp može povećati koncentracije tipranavira u plazmi.
Co- administration of grapefruit juice with aliskiren 150 mg resulted in a 61% decrease in aliskiren AUC and co-administration with aliskiren 300 mg resulted in a 38% decrease in aliskiren AUC.
Istodobna primjena soka od grejpa s aliskirenom 150 mg rezultirala je smanjenjem AUC-a aliskirena za 61%, dok je istodobna primjena s aliskirenom 300 mg rezultirala smanjenjem AUC-a aliskirena za 38%.
Co- administration of grapefruit juice with aliskiren 150 mg resulted in a 61% decrease in aliskiren AUC and co-administration with aliskiren 300 mg resulted in a 38% decrease in aliskiren AUC.
Istodobna primjena soka od grejpa s aliskirenom150 mg rezultirala je smanjenjem AUC-a aliskirena za 61%, dok je istodobna primjena s aliskirenom 300 mg rezultirala smanjenjem AUC-a aliskirena za 38%.
Co- administration of higher doses of either efavirenz or carbamazepine has not been studied.
Istodobna primjena viših doza efavirenza ili karbamazepina nije ispitivana.
Co- administration of ISENTRESS
Istodobna primjena
Co- administration of lapatinib with orally administered digoxin resulted in an approximate 80% increase in the AUC of digoxin.
Istodobna primjena lapatiniba i oralno primijenjenog digoksina rezultirala je povećanjem AUC za digoksin od približno 80%.
Co- administration of lithium and MicardisPlus is not recommended (see section 4.4).
Istodobna primjena litija i MicardisPlusa se ne preporučuje (vidjeti dio 4.4).
Co- administration of multiple doses of linagliptin and metformin did not meaningfully alter the pharmacokinetics of either linagliptin or metformin in healthy volunteers and patients.
Istovremena primjena višekratnih doza linagliptina i metformina nije značajno promijenila farmakokinetiku bilo linagliptina ili metformina u zdravih dobrovoljaca i bolesnika.
Co- administration of orange or apple juice with aliskiren 150 mg resulted in a 62% decrease in aliskiren AUC or in a 63% decrease in aliskiren AUC, respectively.
Istodobna primjena soka od naranče ili jabuke s aliskirenom 150 mg rezultirala je smanjenjem AUC-a aliskirena za 62% odnosno smanjenjem AUC-a aliskirena za 63%.
Co- administration of pazopanib 800 mg once daily and paclitaxel 80 mg/m2 (CYP3A4 and CYP2C8 substrate) once weekly resulted in a mean increase of 25 % and 31 % in paclitaxel AUC and Cmax, respectively.
Istovremena primjena 800 mg pazopaniba jednom dnevno i 80 mg/m2 paklitaksela (supstrat CYP3A4 i CYP2C8) jednom tjedno rezultirala je prosječnim povećanjem AUC za paklitaksel od 25% i Cmax za paklitaksel od 31%.
Co- administration of pioglitazone with rifampicin (an inducer of cytochrome P450 2C8) is reported to result in a 54% decrease in AUC of pioglitazone.
Zabilježeno je da istodobna primjena pioglitazona s rifampicinom (induktor citokroma P450 2C8) rezultira smanjenjem AUC-a pioglitazona za 54%.
Co- administration of posaconazole with sirolimus is not recommended and should be avoided whenever possible.
Istodobna primjena posakonazola i sirolimusa se ne preporučuje i treba je izbjegavati kad god je to moguće.
Co- administration of Rasilez had no significant impact on atorvastatin, metformin or amlodipine pharmacokinetics.
Istodobna primjena Rasileza nije imala značajan utjecaj na farmakokinetiku atorvastatina, metformina ili amlodipina.
Co- administration of telaprevir and medicinal products that induce CYP3A and/or P-gp may decrease telaprevir plasma concentrations.
Istodobna primjena telaprevira i lijekova koji induciraju CYP3A i/ili P-gp može smanjiti koncentracije telaprevira u plazmi.
Co- administration of thiazide may increase the incidence of hypersensitivity reactions of allopurinol.
Istodobna primjena tiazida može povećati incidencija reakcija preosjetljivosti na alopurinol.
Co- administration of Viekirax with other antivirals has not been studied and therefore cannot be recommended.
Istodobna primjena lijeka Viekirax s drugim antiviroticima nije ispitivana te se stoga ne može preporučiti.
Co- administration with EVOTAZ can increase plasma concentrations of medicinal products that are metabolised by CYP2D6 (see sections 4.3 and 4.5).
Istodobna primjena s lijekom EVOTAZ može povisiti plazmatske koncentracije lijekova koje metabolizira CYP2D6 (vidjeti dijelove 4.3 i 4.5).
Co- administration with REYATAZ may result in increased concentrations of the PDE5 inhibitor and an increase in PDE5-associated adverse events, including hypotension, visual changes, and priapism.
Istovremena primjena s lijekom REYATAZ može rezultirati povišenim koncentracijama inhibitora PDE5 i pojačanim nuspojavama povezanima s PDE5, uključujući hipotenziju, poremećaje vida i prijapizam.
Co- treatment with other hepatotoxic medicinal products was frequently present.
Često su istodobno primjenjivani drugi hepatotoksični lijekovi.
Co-administation with ketoconazole did not affect the pharmacokinetics of palonosetron.
Istovremena primjena ketokonazola nije utjecala na farmakokinetiku palonozetrona.
co-administer
primjena darunavira/ritonavira
co-administer
primjena lopinavira/ritonavira
co-administer
primjenjivati
co-administer EVOTAZ with an H2-
primjena lijeka EVOTAZ istodobno
co-administer Kaletra and
primjena lijeka Kaletra i
co-administer OLYSIO
istovremeno primjenjivati
co-administer OLYSIO
preporučuje se terapijsko
co-administer PREZISTA with low
lijeka PREZISTA s niskom dozom
co-administer PREZISTA with low
lijeka PREZISTA s niskom dozom ritonavira i boceprevira.
co-administer PREZISTA with low
PREZISTE s niskom dozom ritonavira sa
Co-administered drug
Istodobno primijenjeni
Co-administered drug
Istodobno primijenjeni lijek, prema terapijskom području
Co-administered drug by
Istodobna primjena
Co-administered drug by
Istodobno primijenjeni
Co-administered drug by
Istodobno primijenjeni lijek, prema terapijskom području
Co-administered drug by therapeutic area
Istodobna primjena
Co-administered drug by therapeutic area
Istodobno primijenjeni
Co-administered medicinal product by therapeutic area
Istodobno primijenjeni lijekovi prema terapijskom podruĉju
Co-administered Medicinal Products Dose of Co-
Istodobno primijenjeni lijek Doza istodobno
Co-administered Medicinal Products Dose of Co-
Istodobno primijenjeni lijek Doza istodobno primijenjeno g lijeka (mg)
Co-administered Medicine
Lijek u istodobnoj primjeni
co-administered with
Istodobna primjena ovih lijekova
co-administered with
istodobno s boceprevirom.
co-administered with
istodobno s vorikonazolom, doza
co-administered with
istovremeno sa
co-administered with
kad se primjenjuju istodobno
co-administered with
kombinaciji s atorvastatinom
co-administered with
primjenjivati istodobno s
co-administered with
promjene u doziranju
co-administered with boosted
arterijske hipertenzije s istodobnom
co-administered with boosted
istodobno s pojačanom PREZISTOM.
co-administered with boosted
pojačanom PREZISTOM rezultirajući
co-administered with boosted
pojačanu PREZISTU, preporučeni
co-administered with boosted
PREZISTOM, primjena bi morala biti u
co-administered with boosted
Primjena karbamazepina s lijekom
co-administered with H2-receptor antagonists without dose adjustments.
Pojačana PREZISTA može se istodobno primijeniti s antagonistima H2-receptora bez prilagodbe doze.
co-administered with low dose
Istodobna primjena Aptivusa s
co-administered with low dose
niskom dozom ritonavira i
co-administered with low dose ritonavir
neće biti potrebna kada se primjenjuje
co-administered with low dose ritonavir is given in combination with tenofovir, particularly in patients with underlying systemic or renal disease, or in patients taking nephrotoxic agents.
istemskom ili bubrežnom bolešću ili kod bolesnika koji uzimaju nefrotoksične
co-administered with low dose ritonavir.
niskom dozom ritonavira.
co-administered with PREZISTA
istodobno s lijekom
co-administered with PREZISTA
istodobno s lijekom PREZISTA u
co-administered with PREZISTA
PREZISTA istodobno primijenjena s
co-administered with PREZISTA
PREZISTOM s niskom dozom ritonavira
co-administered with PREZISTA
PREZISTU s niskom dozom ritonavira,
co-administered with PREZISTA
primijenjenog istodobno s niskom dozom
co-administered with proton
primjenjivati istodobno s
co-administered with tacrolimus.
primjenjuje istovremeno sa
co-administered with telaprevir.
primjenjuje istodobno s telaprevirom.
co-administered with telaprevir.
se primjenjuju istodobno s telaprevirom.
co-administered without dose
se primjenjivati istodobno bez prilagođavanja doze.
co-administered.
kad se primjenjuju istodobno.
co-administering boosted
primjenjuje s β-blokatorima.
co-administering PREZISTA with
PREZISTA s niskom dozom ritonavira je
co-administering PREZISTA with
sedativima/hipnoticima i u obzir treba
co-administering Vitekta and a
primjeni lijeka Vitekta i
Co-administration
Istodobna primjena
co-administration is
istodobna primjena neophodna,
Co-administration is not recommended because it results in a 40 – 60% increase in systemic exposure to didanosine that may increase the risk of didanosine-related adverse reactions (see section 4.5).
Istodobna primjena se ne preporučuje jer rezultira 40 - 60%-tnim povećanjem sistemske izloženosti didanozinu, što može povećati rizik od nuspojava povezanih s didanozinom (vidjeti dio 4.5).
Co-administration is not recommended.
Ne preporučuje se njihova istovremena primjena.
co-administration is required the
istodobna primjena, dnevna doza
co-administration might be
Istodobna primjena ovih
Co-administration of
Istodobna
Co-administration of
Istodobna primjena
Co-administration of
istodobna primjena nevirapina i
Co-administration of
Istovremena primjena
Co-administration of
Istovremena primjena lijeka
co-administration of
Nije bilo ispitivanja interakcija lijeka.
Co-administration of
Nije vjerojatno da bi istodobna
Co-administration of 200 mg bid ketoconazole, a strong inhibitor of CYP3A4, caused an approximate 2-fold increase in cinacalcet levels.
Istodobna primjena 200 mg ketokonazola dva puta dnevno, snažnog inhibitora CYP3A4, uzrokuje otprilike dvostruko povećanje vrijednosti sinakalceta.
Co-administration of 200 mg, twice daily ketoconazole, a strong inhibitor of CYP3A4, caused an approximate 2-fold increase in cinacalcet levels.
Istodobna primjena 200 mg ketokonazola dva puta dnevno, snažnog inhibitora CYP3A4, uzrokuje otprilike dvostruko povećanje vrijednosti sinakalceta.
Co-administration of a 300 mg tablet with a high fat breakfast reduced maraviroc Cmax and AUC by 33% in healthy volunteers.
Uzimanje tablete od 300 mg istodobno s doručkom s visokim sadržajem masnoća dovodi do smanjenja Cmax i AUC za 33% kod zdravih ispitanika.
Co-administration of a CYP3A4 inducer is expected to reduce the effect of Lojuxta.
Očekuje se da će istodobna primjena induktora CYP3A4 smanjiti učinak Lojuxte.
Co-administration of a strong UGT1A9 inhibitor (e.g. mefenamic acid, diflunisal, and niflumic acid) during regorafenib treatment should be avoided, as their influence on the steady-state exposure of regorafenib and its metabolites has not been studied.
Istodobnu primjenu jakih inhibitora UGT1A9 (primjerice mefeminske kiseline, diflunizala i nifluminske kiseline) tijekom liječenja regorafenibom mora se izbjegavati jer njihov utjecaj na izloženost stanju dinamičke ravnoteže regorafeniba i njegovih metabolita nije ispitivan.
Co-administration of aliskiren and amlodipine does not cause meaningful changes in the steady-state pharmacokinetic exposure (AUC) and the maximum concentration (Cmax) of either component in healthy volunteers.
Istodobna primjena aliskirena i amlodipina u stanju dinamičke ravnoteže ne uzrokuje značajne promjene farmakokinetičke izloženosti (AUC) i maksimalne koncentracije (Cmax) nijedne komponente u zdravih dobrovoljaca.
Co-administration of aliskiren with either metformin (↓28%), amlodipine (↑29%) or cimetidine (↑19%) resulted in between 20% and 30% change in Cmax or AUC of aliskiren.
Istodobna primjena aliskirena bilo s metforminom (↓28%), amlodipinom (↑29%) ili cimetidinom (↑19%) rezultirala je promjenom Cmax ili AUC-u aliskirena između 20% i 30%.
Co-administration of aliskiren with either metformin (↓28%), amlodipine (↑29%) or cimetidine (↑19%) resulted in between 20% and 30% change in Cmax or AUC of Rasilez.
Istodobna primjena aliskirena bilo s metforminom (↓28%), amlodipinom (↑29%) ili cimetidinom (↑19%) rezultirala je promjenom Cmax ili AUC-u Rasileza između 20% i 30%.
Co-administration of antipsychotic medicinal products with pramipexole should be avoided (see section 4.5).
Treba izbjegavati istodobnu primjenu antipsihotičnih lijekova i pramipeksola (vidjeti dio 4.5.)
Co-administration of Aptivus, co- administered with low dose ritonavir, and pravastatin should be initiated with the lowest dose (10 mg/day) of pravastatin, titrated to treatment response, and accompanied with careful clinical monitoring for pravastatin associated symptoms as described in the label of pravastatin.
Istodobna primjena Aptivusa s niskom dozom ritonavira i pravastatina počinje najnižom dozom (10 mg/dan) pravastatina, titriranom do terapijskog odgovora, uz pažljivo kliničko praćenje radi nuspojava pravastatina.
Co-administration of Aptivus, co- administered with low dose ritonavir, and pravastatin should be initiated with the lowest dose (10 mg/day) of pravastatin, titrated to treatment response, and accompanied with careful clinical monitoring for pravastatin associated symptoms as described in the label of pravastatin.
Istodobna primjena Aptivusa s niskom dozom ritonavira i pravastatina počinje s najnižom dozom (10 mg/dan) pravastatina, titriranom do terapijskog odgovora, te uz pažljivo kliničko praćenje radi nuspojava pravastatina.
Co-administration of Aptivus, co- administered with low dose ritonavir, and rosuvastatin should be initiated with the lowest dose (5 mg/day) of rosuvastatin, titrated to treatment response, and accompanied with careful clinical monitoring for rosuvastatin associated symptoms as described in the label of rosuvastatin.
Istodobna primjena Aptivusa s niskom dozom ritonavira i rosuvastatina započinje najnižom dozom (5 mg/dan) rosuvastatina, titriranom do terapijskog odgovora, uz pažljivo kliničko praćenje radi nuspojava rosuvastatina.